- ACL Friday states it has terminated the development program designed to evaluate the benefit of anecortave acetate treatment on the risk for developing sight-threatening choroidal neovascularization secondary to age-related macular degeneration. The decision followed a planned interim analysis of studies C-02-60 A and B that was performed after 2,546 patients had completed the 24 month time point. In this analysis, anecortave acetate showed no effect on the primary or secondary endpoints. In addition to terminating studies C-02-60 A and B, the company also terminated two smaller studies with an identical design that were being conducted in Asia, C-04-30 and C-05-34.
- The company continues to study anecortave acetate administered as an anterior juxtascleral depot to reduce intraocular pressure in patients with open-angle glaucoma.

Other headlines for [ACL]

• ACL Yesterday 06:00am
  Alcon Inc Wachovia Raised ACL to Outperform from Market Perform
  
• ACL 10/28/2008 12:19pm
  Alcon Inc Merrill Lynch Cuts ACL to Neutral from Buy, price target: $105.00- price target cut to $105 from $178
  
• ACL 10/24/2008 09:08am
  Alcon Inc Wachovia Cuts ACL to Market Perform from Outperform
  
• ACL 10/24/2008 06:39am
  Alcon Inc Merrill Lynch Cuts ACL to Neutral from Buy, price target: $105- price target cut to $105 from $178
  
• ACL 10/23/2008 06:05am
  Alcon Inc JPMorgan Cuts ACL to Neutral from Overweight
  

Healthcare sector headlines

• MAKO Today 07:46am
  MAKO Surgical Receives FDA Clearance to Market Both Its Version 2.0 Tactile Guidance System and Its Bicompartmental Knee Resurfacing Implant System- Announced it received two 510(k) clearances from the US FDA to more...
  
• UNH Today 07:40am
  UnitedHealth Group Inc Guides 2009 Commercial Enrollment down 1-1.5M y/y; Full year decline of 450-800K commercial risk based members- Sees 2009 Medicare advantage enrollemnt up 10-135K y/y - Sees 2009 Medicade more...
  
• MYL Today 07:30am
  Mylan Laboratories Inc Announces settlement agreement with Novartis related to Femara First-to-File Opportunity- Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole more...
  
• XNPT Today 07:30am
  XenoPort Inc Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease- The primary analysis comparing XP19986 to placebo did not reach more...
  
• TGEN Today 07:30am
  Targeted Genetics Corp Realigns product development priorities; Implements cost reduction measures- To focus on its ocular and neurological product candidates and its first use of expressed RNAi - Company has reduced its more...